{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.7643.3.1009","meta":{"versionId":"6","lastUpdated":"2019-01-08T01:00:08.000-05:00","profile":["http://hl7.org/fhir/StructureDefinition/shareablevalueset","http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/valueset-author","valueString":"Oncology Nursing Society Author"},{"url":"http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate","valueDate":"2022-12-15"},{"url":"http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate","valueDate":"2019-01-08"}],"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.7643.3.1009","identifier":[{"system":"urn:ietf:rfc:3986","value":"urn:oid:2.16.840.1.113883.3.7643.3.1009"}],"version":"20190108","name":"CheckpointInhibitorsWithPotentialToCauseGrade3OrHigherFatigue","title":"Checkpoint Inhibitors with Potential to Cause Grade 3 or Higher Fatigue","status":"active","experimental":false,"date":"2019-01-08T01:00:08-05:00","publisher":"Oncology Nursing Society Steward","jurisdiction":[{"coding":[{"system":"urn:iso:std:iso:3166","code":"US"}]}],"purpose":"(Clinical Focus: This value set contains RxNORM concepts for various checkpoint inhibitor agents, regardless of dosage or administration route.),(Data Element Scope: Various drugs used in the treatment of cancer which may cause fatigue.),(Inclusion Criteria: atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab),(Exclusion Criteria: Brand name drugs and drug packs. Chemotherapy and biotherapy agents which may cause fatigue.)","compose":{"include":[{"valueSet":["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.7643.2.1006"]}]},"expansion":{"identifier":"urn:uuid:6659abac-18a3-4c35-8b8d-b23244cc63b2","timestamp":"2023-12-11T03:19:49-05:00","total":11,"contains":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1657005","display":"40 ML ipilimumab 5 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1657012","display":"10 ML ipilimumab 5 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1657190","display":"4 ML nivolumab 10 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1657195","display":"10 ML nivolumab 10 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1657746","display":"pembrolizumab 50 MG Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1657750","display":"4 ML pembrolizumab 25 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1792780","display":"20 ML atezolizumab 60 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1875542","display":"10 ML avelumab 20 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1919507","display":"2.4 ML durvalumab 50 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1919515","display":"10 ML durvalumab 50 MG/ML Injection"},{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","version":"11062023","code":"1991412","display":"24 ML nivolumab 10 MG/ML Injection"}]}}